Halozyme Therapeutics, Inc. (0J2O.L)
USD 61.37
(0.79%)
USD 61.37
(0.79%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 337.57 Million USD | 26.18% |
| 2022 | 267.53 Million USD | -3.03% |
| 2021 | 275.9 Million USD | 91.26% |
| 2020 | 144.25 Million USD | 313.36% |
| 2019 | -67.61 Million USD | 2.48% |
| 2018 | -69.33 Million USD | -185.59% |
| 2017 | 81 Million USD | 197.35% |
| 2016 | -83.21 Million USD | -203.11% |
| 2015 | -27.45 Million USD | 56.45% |
| 2014 | -63.03 Million USD | 21.63% |
| 2013 | -80.43 Million USD | -49.99% |
| 2012 | -53.62 Million USD | -170.3% |
| 2011 | -19.83 Million USD | 63.44% |
| 2010 | -54.25 Million USD | 7.19% |
| 2009 | -58.45 Million USD | -15.91% |
| 2008 | -50.43 Million USD | -79.16% |
| 2007 | -28.15 Million USD | -80.65% |
| 2006 | -15.58 Million USD | -14.91% |
| 2005 | -13.56 Million USD | -49.23% |
| 2004 | -9.08 Million USD | -11390.37% |
| 2003 | -79.09 Thousand USD | -100.8% |
| 2002 | -39.38 Thousand USD | 0.8% |
| 2001 | -39.7 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 117.23 Million USD | 22.71% |
| 2024 Q1 | 95.54 Million USD | -5.44% |
| 2024 Q3 | 163.19 Million USD | 39.21% |
| 2023 FY | 337.57 Million USD | 26.18% |
| 2023 Q1 | 53.8 Million USD | -27.79% |
| 2023 Q2 | 94.45 Million USD | 75.57% |
| 2023 Q4 | 101.03 Million USD | 14.45% |
| 2023 Q3 | 88.27 Million USD | -6.54% |
| 2022 Q4 | 74.5 Million USD | -10.54% |
| 2022 Q3 | 83.29 Million USD | 144.54% |
| 2022 Q1 | 75.67 Million USD | 33.85% |
| 2022 Q2 | 34.06 Million USD | -54.99% |
| 2022 FY | 267.53 Million USD | -3.03% |
| 2021 Q4 | 56.53 Million USD | -25.21% |
| 2021 Q3 | 75.58 Million USD | -18.77% |
| 2021 Q1 | 50.73 Million USD | -34.64% |
| 2021 Q2 | 93.04 Million USD | 83.4% |
| 2021 FY | 275.9 Million USD | 91.26% |
| 2020 Q3 | 40.29 Million USD | 36.35% |
| 2020 FY | 144.25 Million USD | 313.36% |
| 2020 Q4 | 77.62 Million USD | 92.62% |
| 2020 Q2 | 29.55 Million USD | 1017.0% |
| 2020 Q1 | -3.22 Million USD | 89.95% |
| 2019 Q1 | 2.96 Million USD | 4277.46% |
| 2019 FY | -67.61 Million USD | 2.48% |
| 2019 Q4 | -32.06 Million USD | -30.67% |
| 2019 Q3 | -24.53 Million USD | -75.55% |
| 2019 Q2 | -13.97 Million USD | -571.24% |
| 2018 Q4 | -71 Thousand USD | 99.72% |
| 2018 FY | -69.33 Million USD | -185.59% |
| 2018 Q1 | -23.71 Million USD | -118.83% |
| 2018 Q2 | -20.07 Million USD | 15.35% |
| 2018 Q3 | -25.47 Million USD | -26.91% |
| 2017 Q3 | 8.07 Million USD | 131.7% |
| 2017 Q4 | 125.92 Million USD | 1459.11% |
| 2017 Q1 | -27.52 Million USD | -21.93% |
| 2017 Q2 | -25.47 Million USD | 7.44% |
| 2017 FY | 81 Million USD | 197.35% |
| 2016 Q3 | -22.74 Million USD | -4.7% |
| 2016 Q2 | -21.72 Million USD | -34.35% |
| 2016 Q1 | -16.16 Million USD | -395.86% |
| 2016 FY | -83.21 Million USD | -203.11% |
| 2016 Q4 | -22.57 Million USD | 0.74% |
| 2015 Q3 | -23.23 Million USD | -649.21% |
| 2015 Q1 | -13.91 Million USD | -261.23% |
| 2015 Q4 | 5.46 Million USD | 123.52% |
| 2015 FY | -27.45 Million USD | 56.45% |
| 2015 Q2 | 4.23 Million USD | 130.41% |
| 2014 Q3 | -19.02 Million USD | -27.35% |
| 2014 FY | -63.03 Million USD | 21.63% |
| 2014 Q4 | -3.85 Million USD | 79.76% |
| 2014 Q2 | -14.94 Million USD | 40.76% |
| 2014 Q1 | -25.21 Million USD | -18.27% |
| 2013 Q4 | -21.32 Million USD | -15.3% |
| 2013 Q1 | -18.49 Million USD | -319.68% |
| 2013 FY | -80.43 Million USD | -49.99% |
| 2013 Q2 | -22.12 Million USD | -19.6% |
| 2013 Q3 | -18.49 Million USD | 16.4% |
| 2012 Q3 | -20.02 Million USD | -42.58% |
| 2012 Q1 | -15.14 Million USD | 17.84% |
| 2012 Q2 | -14.04 Million USD | 7.21% |
| 2012 Q4 | -4.4 Million USD | 78.0% |
| 2012 FY | -53.62 Million USD | -170.3% |
| 2011 Q1 | -9.65 Million USD | 45.99% |
| 2011 FY | -19.83 Million USD | 63.44% |
| 2011 Q4 | -18.42 Million USD | -457.63% |
| 2011 Q3 | 5.15 Million USD | 66.44% |
| 2011 Q2 | 3.09 Million USD | 132.05% |
| 2010 Q3 | -12.43 Million USD | -2.32% |
| 2010 Q4 | -17.88 Million USD | -43.83% |
| 2010 FY | -54.25 Million USD | 7.19% |
| 2010 Q1 | -11.78 Million USD | 7.01% |
| 2010 Q2 | -12.15 Million USD | -3.09% |
| 2009 Q4 | -12.67 Million USD | 9.06% |
| 2009 Q2 | -17.08 Million USD | -15.75% |
| 2009 Q3 | -13.93 Million USD | 18.4% |
| 2009 FY | -58.45 Million USD | -15.91% |
| 2009 Q1 | -14.75 Million USD | 13.32% |
| 2008 Q4 | -17.02 Million USD | -52.03% |
| 2008 Q2 | -11.37 Million USD | -4.99% |
| 2008 Q1 | -10.83 Million USD | -9.13% |
| 2008 FY | -50.43 Million USD | -79.16% |
| 2008 Q3 | -11.19 Million USD | 1.54% |
| 2007 Q4 | -9.92 Million USD | -19.47% |
| 2007 Q3 | -8.3 Million USD | -42.47% |
| 2007 Q2 | -5.83 Million USD | -42.94% |
| 2007 Q1 | -4.08 Million USD | 12.6% |
| 2007 FY | -28.15 Million USD | -80.65% |
| 2006 Q2 | -3.41 Million USD | 7.03% |
| 2006 Q1 | -3.67 Million USD | -2.63% |
| 2006 FY | -15.58 Million USD | -14.91% |
| 2006 Q4 | -4.66 Million USD | -22.03% |
| 2006 Q3 | -3.82 Million USD | -12.04% |
| 2005 Q3 | -3.76 Million USD | -27.84% |
| 2005 Q4 | -3.57 Million USD | 4.96% |
| 2005 Q1 | -3.27 Million USD | -29.39% |
| 2005 Q2 | -2.94 Million USD | 9.94% |
| 2005 FY | -13.56 Million USD | -49.23% |
| 2004 Q2 | -2.08 Million USD | -73.01% |
| 2004 Q3 | -3.26 Million USD | -56.2% |
| 2004 Q1 | -1.2 Million USD | -2106.86% |
| 2004 FY | -9.08 Million USD | -11390.37% |
| 2004 Q4 | -2.52 Million USD | 22.53% |
| 2003 Q4 | -54.71 Thousand USD | -478.29% |
| 2003 Q3 | -9462.00 USD | -95.13% |
| 2003 FY | -79.09 Thousand USD | -100.8% |
| 2003 Q1 | -9074.00 USD | 56.5% |
| 2003 Q2 | -4849.00 USD | 46.56% |
| 2002 FY | -39.38 Thousand USD | 0.8% |
| 2002 Q4 | -20.86 Thousand USD | -65.43% |
| 2002 Q1 | 12.35 Thousand USD | 0.0% |
| 2002 Q2 | -18.27 Thousand USD | -247.87% |
| 2002 Q3 | -12.61 Thousand USD | 30.99% |
| 2001 FY | -39.7 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -169.18 Million USD | 299.534% |
| Dynavax Technologies Corporation | -37.02 Million USD | 1011.672% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 377.85% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 102.398% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 6506.794% |
| Perrigo Company plc | 151.9 Million USD | -122.234% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 222.307% |
| Illumina, Inc. | -1.06 Billion USD | 131.578% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 95.078% |
| Nektar Therapeutics | -137.42 Million USD | 345.642% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 173.297% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 82.925% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 405.179% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 855.757% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | -73.613% |
| Waters Corporation | 817.67 Million USD | 58.715% |
| Biogen Inc. | 1.29 Billion USD | 73.969% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 223.2% |
| Adicet Bio, Inc. | -152.03 Million USD | 322.033% |
| Evolus, Inc. | -49.23 Million USD | 785.666% |
| bluebird bio, Inc. | -244.26 Million USD | 238.202% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 446.738% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 317.001% |
| FibroGen, Inc. | -281.81 Million USD | 219.786% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 74.995% |
| Homology Medicines, Inc. | -48.25 Million USD | 799.563% |
| Geron Corporation | -193.94 Million USD | 274.057% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 219.633% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 848.878% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 559.322% |
| Myriad Genetics, Inc. | -123.7 Million USD | 372.897% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 91.659% |
| OPKO Health, Inc. | -157.02 Million USD | 314.987% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 434.805% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 165.511% |
| Zoetis Inc. | 3.06 Billion USD | 89.001% |
| Abeona Therapeutics Inc. | -48.2 Million USD | 800.361% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 68.953% |
| Exelixis, Inc. | 170.88 Million USD | -97.545% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 92.163% |
| uniQure N.V. | -282.87 Million USD | 219.338% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 962.192% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 705.449% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 245.616% |
| Verastem, Inc. | -92.08 Million USD | 466.594% |
| Imunon, Inc. | -21.03 Million USD | 1705.169% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 195.433% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 226.043% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | -34.545% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | -214.66% |
| TG Therapeutics, Inc. | 20.63 Million USD | -1536.088% |
| Blueprint Medicines Corporation | -486.27 Million USD | 169.42% |
| Insmed Incorporated | -709.62 Million USD | 147.571% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 186.229% |
| Incyte Corporation | 620.52 Million USD | 45.599% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 146.472% |